• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    British journal of rheumatology

    British journal of rheumatology

    JournalISSN 0263-7103

    年发文量

    研究主题

    论文(6701)

    排序
    1Multifocal Motor Neuropathy with Conduction Block in a Patient with Rheumatoid Arthritis on Infliximab Therapy
    C Rodriguez-Escalera,J Belzunegui,L Lopez-Dominguez,C Gonzalez,M Figueroa
    2005引用:58
    引用
    AI阅读
    加入学术空间
    2Assessment of Patients with Spondyloarthropathies for Treatment with Tumour Necrosis Factor Alpha Blockade.
    S Paul, A Keat

    There is no doubt that the arrival and licensing of two tumour necrosis factor (TNF)-blocking drugs—infliximab and etanercept—for the treatment of ankylosing spondylitis (AS) represents the first major advance in the treatment of this condition since the advocacy of exercises and the introduction of phenylbutazone. These agents have also been shown unequivocally to be effective in a proportion of patients with psoriatic arthritis (PsA), comparable to their effect in rheumatoid arthritis (RA), and anecdotal reports also suggest benefits for patients with enteropathic arthritis, persistent reactive arthritis (ReA) and undifferentiated spondyloarthropathy (SpA). But, as with RA, the availability of these agents places a huge responsibility upon rheumatologists, individually and collectively, to negotiate the poorly charted waters of assessment of disease outcomes, known and potential drug toxicity and potentially massive cost. Moreover, all parties to the negotiation are signed up to the provision of such treatment according to criteria that are wise, transparent and fair. For the SpAs, the opportunities provided by TNFblockade come not a moment too soon but at a difficult time. In recent years huge expertise has developed in the assessment of RA and the development of suitable instruments for that purpose. In contrast, the SpAs have received much less clinical trial attention and clinicians are less well equipped to make objective assessments. Indeed, until the last few years few useful measures were available, especially for the assessment of spinal disease. Fortunately, several groups, notably that at Bath, UK, have developed and validated instruments for measuring such attributes as disease activity, function and pain in AS and more recently an international group of rheumatologists interested in AS have formed the Assessments in Ankylosing Spondylitis (ASAS) working group to attempt to reach consensus over treatment issues which cannot presently be governed by objective criteria such as the presence or absence of joint erosions. Thus, just in the nick of time, a basis has been laid on which to build a framework within which TNFblockade and other biological therapies can reasonably be used in the treatment of SpAs. Unfortunately, at present much of that framework relies heavily on subjective measures, with very limited objectivity. But the need for guidance is now, as our patients need treatment now. Such guidance as emerges must therefore be seen as provisional and requiring regular revision year on year.

    2005引用:9
    引用
    AI阅读
    加入学术空间
    3Rituximab Inefficiency During Type I Cryoglobulinaemia.
    H Nehme-Schuster,A-S Korganow,J-L Pasquali,T Martin
    2005引用:32
    引用
    AI阅读
    加入学术空间
    4Moderately Intensive Exercise in A Temperate Pool for Patients with Rheumatoid Arthritis: A Randomized Controlled Study
    A Bilberg,M Ahlmen,K Mannerkorpi

    Objectives. The aim of this study was to evaluate the effects of moderately intensive pool exercise therapy on patients with rheumatoid arthritis (RA).Methods. Forty-six patients with chronic RA were randomly assigned to a treatment group and a control group. The treatment group (n = 20) exercised in a temperate pool twice a week for 12 weeks. The control group (n = 23) continued with their previous activities. Aerobic capacity, measured by means of a submaximum bicycle test, and the physical component of the SF-36 were chosen as the primary outcome measures. Two tests of muscle endurance were chosen as the secondary outcome measure. Additional functional tests and instruments were included.Results. No significant differences between the groups were found for the primary outcome measures. Significant improvements in the following aspects of muscular function (P < 0.05) were found in the treatment group when their performance was compared with that of the control group: isometric shoulder endurance, grip force, dynamic endurance of lower extremities (chair test) and muscle function of lower extremities. Significant improvements were also found for vitality (SF-36) compared with the control group. The improvements in the training group were maintained for 3 months.Conclusions. Pool exercise therapy of moderate intensity significantly improved muscle endurance in the upper and lower extremities in patients with RA, while no impact on aerobic capacity was found. However, the study population was small and there is a need for further studies with larger populations.

    2005引用:97
    引用
    AI阅读
    加入学术空间
    5Expression of DARC, CXCR3 and CCR5 in Giant Cell Arteritis
    H Bruhl,V Vielhauer, M Weiss,M Mack,D Schlondorff,S Segerer

    OBJECTIVES:Leucocyte infiltration is the hallmark of vasculitis, chemokines being mainly responsible for leucocyte migration into inflamed tissues. The objective was to evaluate the local expression of chemokines and chemokine receptors in biopsies of patients with giant cell arteritis (GCA) compared with arteries from patients with polymyalgia rheumatica (PMR). We studied the expression of CCR5, CXCR3 and that of the Duffy antigen/receptor of chemokine (DARC), a chemokine internalizing receptor (interceptor), in parallel to the expression of the CCR5 ligand RANTES/CCL5.METHODS:Paraffin-embedded tissue sections from six patients with GCA and five patients with PMR were available for immunohistological analysis of chemokine receptor expression. RANTES/CCL5 mRNA was detected in tissue sections by in situ hybridization.RESULTS:In patients with biopsy-proven giant cell arteritis, CCR5 and CXCR3 were highly expressed by infiltrating leucocytes in involved tissue sections. Predominant clustering of CCR5+ and CXCR3+ leucocytes was found in the adventitia and was co-localized with the expression of CCL5/RANTES mRNA. Interestingly, we found marked expression of DARC on adventitial high endothelial venules in vasculitis lesions of patients with GCA, while in arteries from patients with PMR DARC was only expressed on a low number of vessels with flat lining endothelium.CONCLUSIONS:The co-localization of infiltrating CCR5+ and CXCR3+ leucocytes together with CCL5/RANTES and DARC in vasculitis lesions suggests a role for these chemokine receptors in leucocyte infiltration, possibly supported by DARC-mediated vascular presentation of chemokines.

    2005引用:43
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 6701 篇论文

    高被引作者

    作者引用发文
    S Vanderlinden832711
    A CATS81972
    A Calin608926
    Alan Silman556973
    Steven L Garrett54847
    LG KENNEDY50956
    Tim Jenkinson49893
    HC WHITELOCK49471
    Deborah Symmons432936
    David Isenberg416176

    高产作者

    作者引用发文
    David Isenberg416176
    Alan Silman556973
    Peter T Dawes179165
    R.N. Maini240455
    Gs Panayi191655
    B. L. Hazleman207751
    John Richard Kirwan198646
    Paul A. Bacon87845
    Paul Emery199444
    Ferry Breedveld256640

    相关期刊

    Bioorganicheskaia khimiia
    Cell differentiation and development : the official journal of the International Society of Developmental Biologists
    Dermatologica
    Annual reports in medicinal chemistry
    Journal of cancer treatment & diagnosis
    Malaria control & elimination
    Future drug discovery
    Journal of life sciences (Westlake Village, Calif.)
    Central European Journal of Chemistry
    Burger's Medicinal Chemistry and Drug Discovery